Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: Changes in clinical presentation and prognosis

Leukemia and Lymphoma

Volumn 50, Issue 8, 2009, Pages 1261-1268

  Zent, Clive S ^a   Ding, Wei ^a   Reinalda, Megan S ^a   Schwager, Susan M ^a   Hoyer, James D ^a   Bowen, Deborah A ^a   Jelinek, Diane F ^a   Tschumper, Renee C ^a   Call, Timothy G ^a   Shanafelt, Tait D ^a   Kay, Neil E ^a   Slager, Susan L ^a  

^a MAYO CLINIC   (United States)

Author keywords

autoimmune hemolytic anemia; Chronic lymphocytic leukemia; cytopenia; immune thrombocytopenia; pure red blood cell aplasia

Indexed keywords

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOPENIA; DEATH; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PURE RED CELL ANEMIA; TREATMENT OUTCOME; BLOOD COMPONENT THERAPY; COHORT ANALYSIS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPLENECTOMY; SURVIVAL;

IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC, AUTOIMMUNE; BLOOD COMPONENT TRANSFUSION; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RED-CELL APLASIA, PURE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPLENECTOMY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77649283029     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903026492     Document Type: Article

References (28)

1. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Br J Haematol 2008;141:615-621. (Pubitemid 351667621)
2. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
3. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-205.
4. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997. (Pubitemid 26189840)
5. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446-5456.
6. Hamblin T. Autoimmune disease and its management in chronic lymphocytic leukemia. In: Cheson B, editor. Chronic lymphocytic leukemias, 2 edn. New York: Marcel Dekker; 2001. pp 435-458.
7. Mauro F, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95:2786-2792. (Pubitemid 30235886)
8. Kyasa MJ, Parrish RS, Schichman SA, et al. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003;74:1-8.
9. Myint H, Copplestone J, Orchard J, et al. Fludarabinerelated autoimmune hemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995;91:341-344.
10. Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111:1820-1826. (Pubitemid 351451488)
11. Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392. (Pubitemid 24273002)
12. Muller-Hermelink HK, Catovsky D, Montserrat E, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Jaffe E, Harris N, Stein H, Vardiman J, editors. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp 127-130.
13. Zent CS, Kyasa MJ, Evans R, et al. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 2001;92:1325-1330.
14. Hamblin T, Davis Z, Gardiner A, et al. Unmutated Ig V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
15. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
16. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
17. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003;121:287-295. (Pubitemid 36560596)
18. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775. (Pubitemid 36514707)
19. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181-186.
20. Zent CS, Call TG, Hogan WJ, et al. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:1738-1746. (Pubitemid 44649755)
21. Keating MJ, O'brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088. (Pubitemid 46211313)
22. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. Blood 2007;109:405-411. (Pubitemid 46105933)
23. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53. (Pubitemid 40053062)
24. Hamblin T, Oscier D, Young B. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986;39:713-716. (Pubitemid 16069477)
25. Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008;111:1110-1116. (Pubitemid 351213389)
26. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:2092-2095. (Pubitemid 35203453)
27. Kyasa MJ, Hazlett L, Parrish RS, et al. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 2004;45:507-513. (Pubitemid 38196033)
28. Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009;27:904-910.